EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Early colorectal cancer diagnosis: A novel methylated stool DNA model enhanced the diagnostic efficiency

Peng Yun iD, Kamila Kulaixijiang, Jiang Pan, Luping Yang, Nengzhuang Wang, Zheng Xu, Yaodong Zhang, Haifang Cai, Zi-Ye Zhao iD, Min Zhu, Hongli Yan

United European Gastroenterology Journal · 2025

DOI: 10.1002/ueg2.12696 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2025. Verfasst von Peng Yun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Reproductive Medicine Center, The First Affiliated Hospital of Naval Medical University, Shanghai, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, DNA Methylation, Feces, Early Detection of Cancer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Xinjiang Uygur Autonomous Region for Outstanding Young Scientists, National Natural Science Foundation of China, Natural Science Foundation of Xinjiang Uygur Autonomous Region.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methylated stool DNA (sDNA) is a reliable noninvasive biomarker for early colorectal cancer (CRC) diagnosis. However, there are barely any diagnostic panels that can achieve both a sensitivity and specificity exceeding 90% simultaneously.

Objective

We aimed to identify a novel methylated sDNA panel and model for the early diagnosis of CRC.

Methods

We conducted methyl‐CpG binding domain isolated genome sequencing (MiGS) on CpG island methylation phenotype (CIMP)‐positive ( n = 3) and CIMP‐negative CRC tissues ( n = 3) and their corresponding normal adjacent tissues. Subsequently, by utilizing both the aforementioned data and public datasets, we identified a set of promising methylated sDNA markers for CRC. Next, we validated 5 of these genes using pyrosequencing in CRC patients ( n = 31). Then, we developed a combined diagnostic model (CDM) for CRC based on the methylation status of PRDM12 , FOXE1 , and SDC2 by a Training cohort ( n = 231). Finally, the performance of CDM was evaluated in an independent multicenter Validation cohort ( n = 800).

Results

A total of 1062 participants were included in this study. The area under the curve (AUC) of the CDM was 0.979 (95% CI: 0.960–0.997), and the optimal sensitivity and specificity were 97.35% and 99.05%, respectively, in the training cohort ( n = 231). In the independent validation cohort ( n = 800), the AUC was 0.950 (95% CI: 0.927–0.973), along with the optimal sensitivity of 92.75% and specificity of 97.21%. When CRC and advanced adenoma (AAD) were used as diagnostic targets, the model AUC was 0.945 (95% CI: 0.922–0.969), with an optimal sensitivity of 91.89% and a specificity of 95.21%. The model sensitivity for nonadvanced adenoma patients was 68.66%.

Conclusion

The sDNA diagnostic model CDM, developed from both CIMP‐P and CIMP‐N, exhibited exceptional performance in CRC and could serve as a potential alternative strategy for CRC screening.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsDNA MethylationFecesEarly Detection of CancerBiomarkers, TumorHumansFemaleMaleMiddle AgedCpG IslandsAgedSensitivity and SpecificitySyndecan-2ROC CurveTranscription FactorsDNA-Binding Proteins

Stichwörter der Autor:innen

CRCPRDM12biomarkerscarcinomaearly diagnosisepigeneticsgenesgeneticsneoplasiascreening

Substanzen

Biomarkers, TumorSDC2 protein, humanSyndecan-2Transcription FactorsDNA-Binding Proteins

Autor:innen und Institutionen

  • Reproductive Medicine Center, The First Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Department of Pathology, Karamay Central Hospital of Xinjiang, Karamay, China.
  • Xinjiang Key Laboratory of Clinical Genetic Testing and Biomedical Information, Karamay, China.
  • Xinjiang Clinical Research Center for Precision Medicine of Digestive System Tumors, Karamay, China.
  • Reagent R&D Department, Xiamen Sciendox Biotechnology Co., Ltd., Xiamen, China.
  • Central Laboratory, Seventh People's Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

ORCID-Profile: Peng Yun, Zi-Ye Zhao

Förderung

  • Natural Science Foundation of Xinjiang Uygur Autonomous Region for Outstanding Young Scientists
  • National Natural Science Foundation of China
  • Natural Science Foundation of Xinjiang Uygur Autonomous Region

Zitieren

APA

Yun, P., Kulaixijiang, K., Pan, J., Yang, L., Wang, N., Xu, Z., Zhang, Y., Cai, H., Zhao, Z. Y., Zhu, M., & Yan, H. (2025). Early colorectal cancer diagnosis: A novel methylated stool DNA model enhanced the diagnostic efficiency. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12696

Vancouver

Yun P, Kulaixijiang K, Pan J, Yang L, Wang N, Xu Z, et al. Early colorectal cancer diagnosis: A novel methylated stool DNA model enhanced the diagnostic efficiency. United European Gastroenterology Journal. 2025. doi:10.1002/ueg2.12696

BibTeX
@article{Yun2025,
  author = {Yun, Peng and Kulaixijiang, Kamila and Pan, Jiang and Yang, Luping and Wang, Nengzhuang and Xu, Zheng and Zhang, Yaodong and Cai, Haifang and Zhao, Zi-Ye and Zhu, Min and Yan, Hongli},
  title = {Early colorectal cancer diagnosis: A novel methylated stool DNA model enhanced the diagnostic efficiency},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  doi = {10.1002/ueg2.12696}
}
Kostenlos starten →